Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

DRonabinol Behandling av OSA (DROSA)

2 november 2026 uppdaterad av: VA Office of Research and Development

Riktad behandling av obstruktiv sömnapné med dronabinol: Proof of Concept och klinisk fas II-prövning

This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Obstructive sleep apnea (OSA), is a serious respiratory disorder that involves repetitive cessation of breathing during sleep. It is estimated that 15-20 million people in the United States suffer from OSAS, which has been linked to increased risk for hypertension, heart failure, depression, and diabetes. The current standard of care for OSA, positive airway pressure (PAP), involves a mechanical device with low patient tolerance and adherence. Upper airway surgical approaches are also an option but are invasive and often unsuccessful. Effective drug treatments for OSA remain to be identified.

This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.

Studietyp

Interventionell

Inskrivning (Beräknad)

120

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Illinois
      • Chicago, Illinois, Förenta staterna, 60612
        • Rekrytering
        • Jesse Brown VA Medical Center, Chicago, IL
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Bharati Prasad, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

Inte äldre än 65 år (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

1. AHI 15-50 per hour on pre-treatment polysomnography

Exclusion Criteria:

  1. Positive Airway Pressure (PAP) treatment of obstructive sleep apnea (OSA): use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data

  2. Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use > 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report

  3. History of upper airway surgery for OSA (except adenotonsillectomy)

  4. Central or mixed apneas >25% of respiratory events on diagnostic polysomnography

  5. Arterial oxygen saturation < 75% for > 5% sleep time on pretreatment polysomnography

  6. Body mass index > 45 kilograms per square meter (kg/m2)

  7. If post-bariatric surgery, weight must be stable ±5% (per electronic medical records) for at least 6 months before the first dose of the study drug

  8. Active enrollment in a weight loss program

  9. Shiftwork within 3 months of enrollment

  10. High-risk occupation: commercial driver and pilot

  11. Motor vehicle accident or near-miss incident within 1 year of enrollment

  12. Current drug or habitual alcohol use or positive urine drug screen

  13. Comorbid medical and psychiatric disorders:

    1. Primary sleep disorders: e.g., narcolepsy, restless legs syndrome
    2. Uncontrolled mood disorder or a diagnosis of schizophrenia
    3. Initiation of new antidepressant or antipsychotic medication within 3 months
    4. Identified as high-risk for suicide in electronic health records
    5. Uncontrolled medical disorders (coronary heart disease, arrhythmia, congestive heart failure, chronic obstructive pulmonary disease, chronic hypoxemic or hypercapnic respiratory failure, stroke within 6 months of enrollment, chronic liver or kidney disease, autoimmune disorders)
  14. Use of sedative-hypnotic medications within 30 days of enrollment

  15. Complete blood count or liver function test values more than 1.5 times the upper limit of normal

  16. Pregnancy

  17. Allergy to cannabinoids or sesame oil

  18. Average weekly alcohol consumption of more than 10 servings

  19. Participation in other investigational protocols within 30 days of enrollment

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Single group

Open label Dronabinol treatment for two weeks.

Open label Dronabinol treatment for two weeks.

Andra namn:
  • Marinol

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Apnea Hypopnea Index (AHI)
Tidsram: 2 weeks

The change in AHI after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
T<90
Tidsram: 2 weeks

The change in time below 90% oxygen saturation (T<90) after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Psychomotor Vigilance Test (PVT)
Tidsram: 2 weeks

The change in Lapses on Psychomotor Vigilance Test (PVT) after two weeks of Dronabinol treatment will be determined from before and after treatment PVT using a 10 minute protocol.

2 weeks
24-hour Mean Arterial Blood Pressure (BP)
Tidsram: 2 weeks

The change in 24- hour mean arterial blood pressure after two weeks of Dronabinol treatment will be determined from before and after treatment 24-hiur ambulatory BP recording.

2 weeks
Sleep Efficiency
Tidsram: 2 weeks

The change in sleep efficiency after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks
Rapid Eye Movement (REM) Sleep
Tidsram: 2 weeks

The change in REM sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks
Slow Wave Sleep
Tidsram: 2 weeks

The change in slow wave sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks
Treatment Satisfaction Questionnaire for Medication (TSQM)
Tidsram: 2 weeks

Patient reported treatment satisfaction. TSQM scores have a range of 0 to 100, with higher scores indicating higher satisfaction.

2 weeks
Epworth Sleepiness Scale (ESS)
Tidsram: 2 weeks

The change in Epworth Sleepiness Scale (ESS) will be measured after two weeks of Dronabinol treatment.

ESS scores have a range of 0 to 24, with higher scores indicating greater sleepiness.

2 weeks
Functional Outcomes of Sleep Questionnaire (FOSQ)
Tidsram: 2 weeks

The change in Functional Outcomes of Sleep Questionnaire (FOSQ) will be measured after two weeks of Dronabinol treatment.

FOSQ score ranges from 5-20, with higher scores indicating better functional status.

2 weeks
Pittsburgh Sleep Quality Index (PSQI)
Tidsram: 2 weeks

The change in Pittsburgh Sleep Quality Index (PSQI) will be measured after two weeks of Dronabinol treatment.

The PSQI score ranges from 0 to 21. Higher scores indicate poorer sleep quality.

2 weeks
Insomnia Severity Index (ISI)
Tidsram: 2 weeks

The change in Insomnia Severity Index (ISI) will be measured after two weeks of Dronabinol treatment.

ISI ranges from 0 to 28, with higher scores indicating greater sleep disturbance.

2 weeks
Post-Traumatic Stress Disorder; PTSD checklist (PCL-5)
Tidsram: 2 weeks

The change in Post-Traumatic Stress Disorder; PTSD checklist (PCL-5) will be measured after two weeks of Dronabinol treatment.

PCL-5 scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.

2 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Bharati Prasad, MD, Jesse Brown VA Medical Center, Chicago, IL

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

25 augusti 2025

Primärt slutförande (Beräknad)

31 mars 2027

Avslutad studie (Beräknad)

31 mars 2027

Studieregistreringsdatum

Först inskickad

21 juni 2024

Först inskickad som uppfyllde QC-kriterierna

21 juni 2024

Första postat (Faktisk)

27 juni 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera